3rd Annual Antibody Summit: Bispecifics & Multispecifics
15-16

May 2019

Austria

Vienna

Hilton Garden Inn Vienna South

Hertha-Firnberg-Straße 5, 1100

Co-located with 4th Annual Antibody Drug Conjugates (ADCs) Summit: From Target to Therapeutics

We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 15 - 16, 2019 in Vienna, Austria. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The Summit will shed light on the progress in discovery, development and therapeutics of novel protein therapeutics, and the latest breakthrough engineering next-generation antibody...

We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 15 - 16, 2019 in Vienna, Austria. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The Summit will shed light on the progress in discovery, development and therapeutics of novel protein therapeutics, and the latest breakthrough engineering next-generation antibody formats. It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Vienna in May!

more info
Who Should Attend

Chief Executives, Vice Presidents, Directors, Heads, Leaders and Managers specializing in:

  • Antibody Discovery
  • Analytical & Formulation
  • Bioassay
  • Biologics
  • Cancer
  • CD3
  • Clinical trials / Development
  • Central Nervous System (CNS) / Neuroscience
  • Drug Development
  • EGFR
  • Fc
  • Genetics
  • Immunogenicity
  • In Silico Modelling / Quantitative Science
  • Manufacturing
  • Multispecific Antibody
  • Oncology
  • Preclinical Models
  • Process Development / Developability
  • Protein Chemistry
  • T-cell
  • Theranostics
  • Toxicities / Toxicology
  • Yield
  • Antibody Engineering
  • Blood Brain Barrier
  • Biochemistry
  • Bispecifics
  • Cancer Immunotherapies
  • Checkpoint
  • CMC / Regulatory
  • Combination Therapies
  • Drug Targets / Targets Selection
  • Ex Vivo Assay
  • FIH
  • Imaging
  • Immunology
  • Mab
  • Monoclonal Antibodies
  • Neuroscience
  • Pharmacokinetics (PK)
  • Process / Manufacturing Quality
  • Protein
  • Screening / Modelling
  • Target Toxities
  • Therapeutic Antibodies
  • Tumours
Key Practical Learning Points of the Summit

CMC strategies for developing manufacturing processes and product quality characterization of bispecifics / multispecifics
Emerging approaches, science and tech to engineer and to bring to market more targeted, stable extended half-life, and functional multispecifics
Advanced analytical development and characterization for novel protein formats
Imaging, theranostic, and other new applications of bispecifics in oncology and beyond
Accelerating translation and clinical development progress of bispecific antibody and combination therapies
Speakers
Dr. Maximilian Woisetschlaeger, CH

Director of Biologics; Group Head Immunomodulation

Novartis Pharma AG

Dr. Siddharth Sukumaran, US

Senior Scientist/PKPD Therapeutic Area LeaderImmunology/Pharmacology Team Leader

Genentech

Dr. Christian Cimander, DK

Senior Director, CMC Operations

Genmab

Dr. Ercole Rao, DE

Group Leader Global Biotherapeutic

Sanofi

Dr. Thomas Huber, CH

Senior Investigator II / NIBR Biologics center

Novartis Pharma AG

Dr. Andrew Goodearl, US

Senior Director, Biologics Discovery

Abbvie

Dr. Benjamin Smith, US

Scientist II / Biologics Drug Discovery / CNS Delivery

Biogen

Dr. Elke Glasmacher, DE

Dept. Head & Senior Principal Scientist in Large Molecule Research at pRED & Independent Investigator

Roche & Helmholtz Zentrum München

Dr. Laura von Schantz, SE

Director of Antibody Engineering

Alligator Bioscience

Dr. Weon-Kyoo You, KR

R&D Head

ABL Bio, Inc.

Dr. Mariangela Figini, IT

Group leader

Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy

Annual

Events

Sponsors and Partners

Sponsor

Sponsor

Sponsor

Media partner

Media partner

Media partner

Media partner

"